Pembrolizumab (for recurrent/metastatic NPC)
Treatment for Nasopharynx cancer
Effectiveness
65%
Safety Score
45%
Clinical Trials
3
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
0
Pembrolizumab (for recurrent/metastatic NPC) Outcomes
for Nasopharynx cancer
Efficacy Outcomes
Overall Effectiveness
+65%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
1 active trial recruiting for Pembrolizumab (for recurrent/metastatic NPC) in Nasopharynx cancer
Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC
NCT03813394ACTIVE NOT RECRUITINGPHASE1, PHASE2
48 participants
INTERVENTIONAL
Singapore, Singapore
Started: May 1, 2019
Completed Clinical Trials
1 completed trial for Pembrolizumab (for recurrent/metastatic NPC) in Nasopharynx cancer
Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)
NCT02611960COMPLETEDPHASE3
233 participants
INTERVENTIONAL
Started: Apr 18, 2016